Previous 10 | Next 10 |
home / stock / flhlf / flhlf news
FILAMENT HEALTH CULTIVATES 70TH PSYCHEDELIC MUSHROOM VARIETY AND ANNOUNCES ANNUAL GENERAL MEETING Canada NewsWire VANCOUVER, BC , June 10, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clin...
Filament Forms Collaboration With Jaguar Health. Filament and Jaguar Health (JAGX, $0.35, Not Rated) have signed a Letter of Intent to develop botanical compounds for psychiatric uses. We believe Filament's expertise in extraction and manufacturing technologies fits well with Jaguar's extensiv...
Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications Canada NewsWire Drug discovery collaboration will leverage the botanical drug development expertise of both companies VANCOU...
VANCOUVER, British Columbia, May 31, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations ...
Filament Health press release (OTC:FLHLF): Q1 Cash and equivalents of over C$3.6 million. For further details see: Filament Health reports Q1 results
FILAMENT HEALTH IS ISSUED SECOND PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE AND REPORTS Q1 RESULTS Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds The Company also reports first quarter 2...
Filament Health (FLHLF) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>
NEW YORK, April 29, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27 th and 28 th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing....
FILAMENT HEALTH ANNOUNCES FOURTH PATENT ISSUANCE Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC , April 27, 2022 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (N...
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences , the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Co...
News, Short Squeeze, Breakout and More Instantly...
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the " Acquiror "), a shareholder of Filament Health Corp. (" Filament "), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the " Common Shares ") from the conversion o...
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...